Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Embolism (Diagnosis) Clear all
Completed No phase listed Observational

COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications

NCT04535128
View directory record Official record
Conditions
Covid19, Thrombosis Embolism, DVT, Pulmonary Embolism, Myocardial Infarction, Stroke
Interventions
No intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
11,000 participants
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jun 10, 2026, 2:28 PM EDT
Completed Phase 1 Interventional

A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

NCT01325558
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
Interventions
ALT-836 in combination with gemcitabine
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Iowa City, Iowa • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Jun 10, 2026, 2:28 PM EDT
Completed Not applicable Interventional

Standard vs. Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism

NCT02758574
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
CDT without ultrasound acceleration, CDT with ultrasound acceleration
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jun 10, 2026, 2:28 PM EDT
Completed No phase listed Observational

Computed Tomography Dose Reduction Using Sequential or Fast Pitch Sprial Technique

NCT01272453
View directory record Official record
Conditions
Coronary Artery Disease, Aortic Aneurysm, Pulmonary Embolism
Interventions
Not listed
Lead sponsor
Gilbert L. Raff, MD
Other
Eligibility
18 Years and older
Enrollment
2,640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
San Diego, California • Boston, Massachusetts • Royal Oak, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Jun 10, 2026, 2:28 PM EDT
Not listed No phase listed Observational

The DARE Warfarin CER Study

NCT03271450
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days), Apixaban: extended treatment (e.g at least 90 days), Apixaban: extended treatment (e.g at least 180 days), Apixaban: extended treatment (e.g at least 270 days), Rivaroxaban: extended treatment (e.g at least 90 days), Rivaroxaban: extended treatment (e.g at least 180 days), Rivaroxaban: extended treatment (e.g at least 270 days), Edoxaban: extended treatment (e.g at least 90 days), Edoxaban: extended treatment (e.g at least 180 days), Edoxaban: extended treatment (e.g at least 270 days), Warfarin: extended treatment (e.g at least 90 days), Warfarin: extended treatment (e.g at least 180 days), Warfarin: extended treatment (e.g at least 270 days)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
416,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jun 10, 2026, 2:28 PM EDT
Terminated Phase 4 Interventional Results available

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

NCT03988842
View directory record Official record
Conditions
Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions
Alteplase, Unfractionated heparin, Placebo, Apixaban
Drug
Lead sponsor
Victor Tapson, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jun 10, 2026, 2:28 PM EDT
Completed Not applicable Interventional

SYMPHONY-PE Study for Treatment of Pulmonary Embolism

NCT06062329
View directory record Official record
Conditions
Acute Pulmonary Embolism, Thromboembolism, Emboli, Pulmonary, Thrombosis, Thrombus; Embolism, Embolism, Cardiovascular Diseases, Vascular Diseases
Interventions
Symphony Thrombectomy System
Device
Lead sponsor
Imperative Care, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Huntsville, Alabama • Los Angeles, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Jun 10, 2026, 2:28 PM EDT
Terminated Phase 2 Interventional Results available

STAT-STatin and Aspirin in Trauma

NCT02901067
View directory record Official record
Conditions
Wounds and Injuries, Venous Thromboembolism
Interventions
Aspirin and Rosuvastatin, Placebo (for Aspirin and Rosuvastatin)
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Jun 10, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

NCT00457002
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
6,758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Jun 10, 2026, 2:28 PM EDT
Not listed Not applicable Interventional

Whole-leg Ultrasound in Pregnant Patients

NCT01319474
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Whole-leg compression ultrasound
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jun 10, 2026, 2:28 PM EDT
Recruiting Not applicable Interventional

Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU

NCT06538376
View directory record Official record
Conditions
Pulmonary Edema, Pneumonia, Atelectasis, Pleural Effusion, Acute Rejection of Lung Transplant (Disorder), Airway Obstruction, Rib Fractures, Acute Copd Exacerbation, Asthma COPD, Pulmonary Embolism, Hemothorax, Pneumothorax, Mesothelioma, Diaphragmatic Paralysis
Interventions
Portable Dynamic Digital Radiography (DDR)
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jun 10, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Jun 10, 2026, 2:28 PM EDT
Completed No phase listed Observational

Multi-Center Human Alert Trial to Prevent DVT and PE

NCT00409136
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions
Human Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2009 · Synced Jun 10, 2026, 2:28 PM EDT
Recruiting Phase 3 Interventional

Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

NCT05591118
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Anticoagulant Therapy, Catheter-Directed Therapy
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 10, 2026, 2:28 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Nudging Provider Adoption of Clinical Decision Support: Implementation of an EHR-Agnostic Pulmonary Embolism Risk Prediction Tool

NCT07249385
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Clinical Decision Support (CDS) tool with Nudges
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
3
States / cities
Manhasset, New York • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 10, 2026, 2:28 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism

NCT05127915
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Adient absorbable filter + best practice VTE prophylaxis, best practice VTE prophylaxis
Device
Lead sponsor
Adient Medical
Industry
Eligibility
18 Years and older
Enrollment
854 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Jun 10, 2026, 2:28 PM EDT
Completed Not applicable Interventional

The Protrieve PROTECTOR Study

NCT06495996
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis
Interventions
Percutaneous mechanical thrombectomy (PMT)
Device
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
15
States / cities
Newport Beach, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 2:28 PM EDT
Suspended No phase listed Observational

Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE

NCT06310018
View directory record Official record
Conditions
Pulmonary Embolism, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions
Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis, Tissue Plasminogen Activator
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jun 10, 2026, 2:28 PM EDT
Completed No phase listed Observational Results available

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

NCT02596230
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
7,797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Long Beach, California • Miami, Florida • Pembroke Pines, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Jun 10, 2026, 2:28 PM EDT
Completed No phase listed Observational

Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center

NCT02502396
View directory record Official record
Conditions
Cancer, Deep-vein Thrombosis of the Lower and Upper Extremities, Pulmonary Embolism, Non-valvular Atrial Fibrillation
Interventions
Retrospective Chart Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jun 10, 2026, 2:28 PM EDT
Completed No phase listed Observational

Outpatient Treatment of PE and DVT in the Emergency Department

NCT02532387
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
Telephone follow-up
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Jun 10, 2026, 2:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk Factors for Venous Thromboembolism

NCT00018772
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Jun 10, 2026, 2:28 PM EDT
Completed No phase listed Observational

Pulmonary Embolism Response to Fragmentation, Embolectomy, & Catheter Thrombolysis: PERFECT

NCT01097928
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Catheter directed debulking of Pulmonary Embolus
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Jun 10, 2026, 2:28 PM EDT
Recruiting Not applicable Interventional

The PERSEVERE Study

NCT06588634
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Thromboembolism
Interventions
FlowTriever System, Standard of Care
Device · Procedure
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
New Haven, Connecticut • Orlando, Florida • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 2:28 PM EDT